Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer
Mariam Elshiaty, Hannah Schindler, Petros Christopoulos
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5632-5632
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 136
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 135
Targeting Breast Cancer Stem Cells
Lu Zhang, Wen‐Ming Chen, Suling Liu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 2, pp. 552-570
Open Access | Times Cited: 112
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 66
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
Christina Claus, Claudia Ferrara, Christian Klein
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 59
Programmable multispecific DNA-origami-based T-cell engagers
Klaus F. Wagenbauer, Nhi Pham, Adrian Gottschlich, et al.
Nature Nanotechnology (2023) Vol. 18, Iss. 11, pp. 1319-1326
Open Access | Times Cited: 50
Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy
Ana Camila Marques, Paulo Costa, Sérgia Velho, et al.
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 216-216
Open Access | Times Cited: 48
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
Antonio Tapia‐Galisteo, Marta Compte, Luís Álvarez-Vallina, et al.
Theranostics (2023) Vol. 13, Iss. 3, pp. 1028-1041
Open Access | Times Cited: 45
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle
Angelika M. Starzer, Matthias Preusser, Anna S. Berghoff
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 39
Alternative Routes of Administration for Therapeutic Antibodies—State of the Art
Aubin Pitiot, Nathalie Heuzé-Vourc’h, Thomas Sécher
Antibodies (2022) Vol. 11, Iss. 3, pp. 56-56
Open Access | Times Cited: 39
Immunotargeting of Cancer Stem Cells
Ayşe Sedef Köseer, Simona Di Gaetano, Claudia Arndt, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1608-1608
Open Access | Times Cited: 30
A Review of Current and Pipeline Drugs for Treatment of Melanoma
Nicole Natarelli, Soo Aleman, Isabella Mark, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 214-214
Open Access | Times Cited: 16
Antibody-drug conjugates: Principles and opportunities
Zhi Xin Phuna, Prashanth Ashok Kumar, Elio Haroun, et al.
Life Sciences (2024) Vol. 347, pp. 122676-122676
Closed Access | Times Cited: 11
Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives
Shuangsi Liao, Xiaoling Li, You Lü, et al.
Small Methods (2025)
Open Access | Times Cited: 1
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access | Times Cited: 1
Glycans as Targets for Drug Delivery in Cancer
Francisca Diniz, Pedro Coelho, Henrique O. Duarte, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 911-911
Open Access | Times Cited: 36
Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth
Zhiqiang Ku, Xuping Xie, Jianqing Lin, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
Ammelie Svea Boje, Lukas Pekar, Katharina Koep, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 8
Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy
Yufei Xiang, Jialu Xu, Briana L. McGovern, et al.
Cell (2024)
Closed Access | Times Cited: 7
Development of a novel electrochemical biosensor based on plastic antibodies for detection of STEAP1 biomarker in cancer
Margarida Carvalho, Rafael Ribeiro Gomes, Sandra M. Rocha, et al.
Bioelectrochemistry (2023) Vol. 152, pp. 108461-108461
Open Access | Times Cited: 16
Trispecific antibodies for cancer immunotherapy
Yin Yao, Yiyin Hu, Fei Wang
Immunology (2023) Vol. 169, Iss. 4, pp. 389-399
Open Access | Times Cited: 14
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
Hui Yuwen, Huajing Wang, Tengteng Li, et al.
Cancer Research (2024) Vol. 84, Iss. 10, pp. 1680-1698
Open Access | Times Cited: 6
Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment
Justyn Fine, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Annual Review of Chemical and Biomolecular Engineering (2024) Vol. 15, Iss. 1, pp. 105-138
Closed Access | Times Cited: 5
Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study
Miriam Blasi, Jonas Kuon, Rajiv Shah, et al.
Clinical Lung Cancer (2023) Vol. 24, Iss. 7, pp. e282-e290
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top